Stay updated with breaking news from Atharva Karulkar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
India’s first CAR-T cell therapy, NexCAR19, is developed through collaboration between the IIT Bombay and Tata Memorial Hospital, in association with industry partner ImmunoACT, a start-up of two students Alka Dwivedi and Atharva Karulkar, and professor Rahul Purwar. TheHealthSite.com
CAR T-cell therapy involves modifying a patient’s T-cells—white blood cells that are integral to the immune system. The lab-modified cells are then infused in the patient to multiply and fight cancerous cells. The therapy costs $400,000 in the US and tenth of that in India. But, does it work?
ImmunoACT intends to make the NexCAR19 (Actaly cabtagene autoleucel) therapy available to its partner hospitals as soon as possible
India Business News: The Indian drug regulator has granted approval to ImmunoACT for its CAR-T cell therapy NexCAR19, designed to treat certain types of blood cancers. The
Indian company ImmunoACT, backed by drug maker Laurus Labs, has received approval from the Central Drugs Standard Control Organization for its CAR-T cell therapy NexCAR19. The therapy is the first of its kind to be developed in India and will be used to treat certain types of blood cancers. ImmunoACT intends to make the drug available to partner hospitals as soon as possible.